Robin L. Smith, MD, President and Chairman of the Board
Dr. Robin L. Smith is a leading global thought leader in the regenerative medicine industry, one of the fastest growing segments of modern-day medicine. With an M.D. from Yale University and an M.B.A. from the Wharton School of Business, Dr. Smith is the former CEO of the NeoStem family of companies, which she led from 2006 to 2015 and established as one of the preeminent healthcare brands focused on the development of cellular therapies. While leading NeoStem, Dr. Smith raised over $200 million, completing six acquisitions and one divestiture. Notably, she helped pioneer the company’s innovative business model, combining proprietary cell therapy development with a successful contract development and manufacturing organization, which provides these services broadly to companies working in the regenerative medicine industry. The company has won an array of industry awards and business recognition during her tenure, including a #1 ranking in the Tri-State region (for two years in a row), and #11 nationally, on Deloitte’s Technology Fast 500™, and Frost & Sullivan’s North American Cell Therapeutics Technology Innovation Leadership Award.
In 2008, Dr. Smith founded The Stem For Life Foundation (SFLF), a nonpartisan, 501(c)3 educational organization devoted to fostering global awareness of the potential for regenerative medicine to treat and cure a range of deadly diseases and debilitating medical conditions, as opposed to merely treating their symptoms. In 2010, in order to bring the charity’s mission to a global audience, Dr. Smith forged a historic, first-of-its-kind partnership with The Vatican. As part of this relationship, The Vatican and SFLF collaborate to create high-profile initiatives that help catalyze interest and development of cellular therapies that could ultimately reduce human suffering on a global scale.
Dr. Smith is well known as a thought leader in regenerative medicine and maintains a regular column on these topics for The Huffington Post. She is a winner of the 2014 Brava! Award, which recognizes top women business leaders in the Greater New York area. She was also a finalist for the 2014 EY Entrepreneur Of The Year award for the New York area, recognizing entrepreneurs who demonstrate excellence and success in the areas of innovation, financial performance and personal commitment to their businesses and communities.
In addition, Dr. Smith has extensive experience serving in executive and board level capacities for various medical enterprises and healthcare-based entities. She currently serves on the Board of Directors of Signal Genetics (NASDAQ: SGNL). In mid-2015, she joined the boards of MYnd Analytics and BioXCell. She also serves on the Board of Directors of the Science and Faith STOQ Foundation in Rome, as well as on the Capital Formation Committee of the Alliance for Regenerative Medicine. She previously served on the Board of Trustees of the NYU Langone Medical Center and is a past Chairman of the Board of Directors for the New York University Hospital for Joint Diseases.
As a business leader, entrepreneur, doctor and philanthropist, Dr. Smith is uniquely positioned to lead the global healthcare industry into the cellular future, where the cells of our bodies will stand as the foundation for a wide array of cures.